Kcnq1 (Kv7.1) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Kcnq1 (Kv7.1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), also known as Kv7.1, is a gene encoding a voltage-gated potassium channel subunit. KCNQ1 forms homomeric or heteromeric channels that generate the slowly activating delayed rectifier potassium current (IKs). These channels are critical for cardiac repolarization and epithelial electrolyte transport.
| Property | Value |
|---|---|
| Symbol | KCNQ1 |
| Full Name | Potassium Voltage-Gated Channel Subfamily Q Member 1 |
| Synonyms | Kv7.1, KCNA1, LQT1 |
| Chromosomal Location | 11p15.5 |
| NCBI Gene ID | 3785 |
| OMIM ID | 607542 |
| Ensembl ID | ENSG00000143338 |
| UniProt ID | P51787 |
| Protein Length | 676 amino acids |
| Molecular Weight | ~75 kDa |
The KCNQ1 gene consists of 19 exons spanning approximately 19 kb of genomic DNA on chromosome 11p15.5. This region is within the imprinted domain associated with Beckwith-Wiedemann syndrome. The gene produces multiple transcript variants through alternative splicing.
KCNQ1 is a voltage-gated potassium channel with distinctive domains:
The channel assembles as a tetramer, with each subunit contributing to the functional channel.
KCNQ1 channels perform essential functions in various tissues:
In cardiac myocytes, KCNQ1:
In epithelial cells, KCNQ1:
In neurons, KCNQ1 (as Kv7.1):
KCNQ1 exhibits broad expression:
KCNQ1 mutations cause the most common form of long QT syndrome:
Homozygous/compound heterozygous KCNQ1 mutations:
Gain-of-function mutations:
Rare associations with seizure disorders:
Potential roles:
| Approach | Description | Status |
|---|---|---|
| Beta-blockers | First-line LQT1 treatment | FDA approved |
| Potassium channel activators | Flavinoids (e.g., nicorandil) | Research |
| Gene therapy | AAV-KCNQ1 delivery | Preclinical |
Kcnq1 (Kv7.1) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Kcnq1 (Kv7.1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Wang J, et al. (2010). "KCNQ1: Structure, function, and regulation." Journal of Molecular and Cellular Cardiology. 49(2): 203-213.
[2] Jespersen T, et al. (2005). "The KCNQ1 potassium channel: from gene to physiological function." Physiology. 20: 408-416.
[3] Hedley PL, et al. (2009). "The genetic basis of long QT and short QT syndromes." Heart Rhythm. 6(8): 1139-1149.
[4] Neyroud N, et al. (1997). "A novel mutation in the potassium channel gene KCNQ1 causes long QT syndrome." Nature Genetics. 15(2): 186-189.
[5] Brown DA, et al. (2017). "Neuronal KV7 (KCNQ) channels and their modulators as therapeutic targets." Neuropharmacology. 113: 620-633.